Drugs / LYN00101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03644459 | Apr 2019 → Jun 2020 | cervical cancer, colorectal cancer, gastric cancer, ovarian cancer | Lynkcell Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYN00101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03644459 ↗ |
| Action | Inhibit | “Monoclonal antibody LYN00101 is not only a potent inhibitor of VEGF” NCT03644459 ↗ |